Katharine A. McNeill

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/507c4f00-3934-11ed-9b41-f32856b0701a.jpg

First Name

Katharine

Last Name

McNeill

NPI

1598995730

Faculty ID

15494

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

1542

Is Open Scheduling

Off

Ioannis Mantzaris

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b67e5d80-3938-11ed-a06a-83625b154202.jpg

First Name

Ioannis

Last Name

Mantzaris

NPI

1871865519

Faculty ID

14586

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

57027

Is Open Scheduling

Off

Della F. Makower

https://assets.montefioreeinstein.org/profiles/images/physphoto/Makower_Della_MD_420x504.jpg

First Name

Della

Last Name

Makower

NPI

1578559910

Faculty ID

6729

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>My research is focused on breast cancer management, and on care delivery and support for breast cancer patients.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3965

Is Open Scheduling

Off

Kenneth G. Liu

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/62a47410-3938-11ed-9b41-f32856b0701a.jpg

First Name

Kenneth

Last Name

Liu

NPI

1174840888

Faculty ID

15135

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

57009

Is Open Scheduling

Off

Shalom Kalnicki

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/89820450-b883-11ee-8618-fda8dc77c52b.jpg

First Name

Shalom

Last Name

Kalnicki

NPI

1942381371

Faculty ID

9551

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Kalnicki, a radiation oncologist, focuses on new technologies in the radiation treatment of cancer. He was a pioneer in the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. Another area of interest is the use of stereotactic guidance in radiation treatment, specifically for stereotactic radiosurgery (SRS). All enhance precision of tumor targeting with radiation therapy, increasing dose to the tumor, while sparing surrounding normal tissues.<br />&nbsp;<br />Dr. Kalnicki's research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies. His clinical interests focus on head and neck, prostate, and breast cancers.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Radiation Oncology

Research Focus

An active researcher, Dr. Kalnicki is currently investigating innovative methods of radiation planning and delivery, including Intensity Modulated Radiation Therapy (IMRT), PET-CT fusion for radiation planning, 4-D treatment planning, target motion manage

Elsevier Profile

EMR ID

4214

Biography

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. He pioneered the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, stereotactic body radiation therapy (SBRT) and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p><p>Dr. Kalnicki earned his medical degree at the University of Sao Paulo Medical School in Sao Paulo, Brazil. He completed his residency and fellowship in radiotherapy at Montefiore and Albert Einstein College of Medicine. He came to Montefiore and Einstein from the University of Pittsburgh, School of Medicine, where he was Vice Chairman for Clinical Affairs and Director of Radiation Oncology at the University of Pittsburgh Cancer Institute. </p><p>Prior to joining the University of Pittsburgh Cancer Institute, Dr. Kalnicki served as Chairman of the Department of Radiation Oncology at Allegheny University of Health Sciences in Pittsburgh. He is a member of many prominent professional societies. He has authored numerous articles and abstracts during his career and is a recipient of several awards, including the Fellowship Award from the American College of Radiation Oncology.</p>

Is Open Scheduling

Off

Rafi Kabarriti

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/05986ec0-4373-11ee-9d6f-374ce67539f5.jpg

First Name

Rafi

Last Name

Kabarriti

NPI

1811200256

Faculty ID

15596

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Rafi Kabarriti, MD, is a cum laude graduate of Columbia University with a bachelor&rsquo;s degree in biochemistry and economics.&nbsp;&nbsp;He earned his medical degree at Albert Einstein College of Medicine and completed an internship in internal medicine at Mount Sinai St. Luke's and Mount Sinai West Hospital and a residency in radiation oncology at Montefiore Medical Center, where he was chief resident in the Department of Radiation Oncology.&nbsp;&nbsp;Dr. Kabarriti is the recipient of the prestigious American Society of Clinical Oncology and Conquer Cancer Foundation Young Investigator Award, Empire Clinical Research Investigator Program Fellowship and AIDS Malignancy Consortium fellowship Award.&nbsp;&nbsp;He is also funded by the NIH K12 Paul Calabresi Career Development Award for Clinical Oncology.&nbsp;&nbsp;His research has been selected for oral presentations at national and international meetings including the annual meetings of the American Society for Radiation Oncology, European Society for Radiotherapy, and the European ORL-HNS Congress. Dr. Kabarriti is author and co-author of over 40 articles published in peer-reviewed journals including the Journal of Clinical Oncology, International Journal of Radiation Oncology, Biology, and Physics, Oral Oncology and Head and Neck.&nbsp;His research focus is on optimizing radiation therapy for head and neck and gastrointestinal cancers and combining radiation therapy with novel therapeutics and immunotherapy to improve outcomes for these patients.&nbsp;&nbsp;He is the principal investigator of multiple clinical trials including investigator-initiated clinical trials as well as the local PI on cooperative and international studies.&nbsp;&nbsp;&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Treatment of head and neck, gastrointestinal and other cancer types, and use of advanced technologies in radiation oncology including image guidance, stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS).

Research Focus

Novel therapeutics for the monitoring and management of radiation-induced toxicities using the liver as a model; Integration of radiation therapy with immunotherapy agents to produce a strong anti-tumor systemic immune response.

Elsevier Profile

Selected Publications

<h3>Selected Publications:</h3>
<p>1. &nbsp;<strong>Kabarriti, R</strong>. Ohri, N. Hannan, R. Tishbi, N.&nbsp;Baliga, S. McGovern, KP. Mourad, WF.&nbsp;Ghavamian, R. Kalnicki, S. Guha, C. Garg, MK. PSA Decline During Salvage Radiation Therapy Following Prostatectomy Is Associated With Reduced Biochemical Failure.&nbsp;&nbsp;Practical Radiation Oncology, 2014 Feb 21. &nbsp;</p>
<p>2.&nbsp;&nbsp;<strong>Kabarriti, R</strong>. Guha, C. Hedgehog Signaling and Radiation Induced Liver Injury: A Delicate Balance.&nbsp;&nbsp;Hepatology International, 2014 Jul;8(3):316-20.</p>
<p>3.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Mark D, Fox J, Kalnicki S, Garg MK.&nbsp;Proton therapy for the treatment of pediatric head and neck cancers: A review. Int J Pediatr Otorhinolaryngol. 2016 Jan;79(12)</p>
<p>4. &nbsp;<strong>Kabarriti R</strong>, Quinn TJ, Ewart MR, Mehta KJ, Lomita C, Geller DS, Kalnicki S, Fox JL. Neoadjuvant radiation therapy for the management of myoepithelial carcinoma of the upper extremity. Int J Cancer. 2018 Feb 15;142(4), PMCID: PMC6200873</p>
<p>5.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Bontempo A, Romano M, McGovern KP, Asaro A, Viswanathan S, Kalnicki S, Garg MK. The Impact of Dietary Regimen Compliance on Outcomes for HNSCC Patients Treated with Radiation Therapy. Supportive Care in Cancer, 2018 Sep;26(9):3307-3313; PMID: 29671062</p>
<p>6. &nbsp;Ohri N,&nbsp;<strong>Kabarriti R</strong>, Kaubisch A, Guha C. RFA versus SBRT for HCC: Caution when Interpreting Observational Data; Journal of Clinical Oncology, 2018 Aug 20;36(24):2558; PMID: 29945527</p>
<p>7. &nbsp;Baliga S*,&nbsp;<strong>Kabarriti R*</strong>, Jiang J, Mehta V, Guha C, Kalnicki S, Smith RV, Garg, MK. Utilization of Transoral Robotic Surgery (TORS) in Patients with Oropharyngeal Squamous Cell Carcinoma and its impact on Survival and use of Chemotherapy.&nbsp;&nbsp;Oral Oncology, 2018 Nov;86:75-80; PMID: 30409323&nbsp;&nbsp;&nbsp;*co-first author</p>
<p>8. &nbsp;Brodin NP,&nbsp;<strong>Kabarriti R</strong>, Pankuch M, Schechter CB, Gondi V, Kalnicki S, Guha C, Garg MK, Tom&eacute; WA.&nbsp;&nbsp;A Quantitative Clinical Decision-support Strategy Identifying Which Oropharyngeal Head and Neck Cancer Patients may Benefit the Most from Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Nov 26.&nbsp;&nbsp;PMID: 30496877</p>
<p>9. &nbsp;Barahman M, Asp P, Roy-Chowdhury N, Kinkhabwala M, Roy-Chowdhury J,&nbsp;<strong>Kabarriti R</strong>, Guha C.&nbsp;&nbsp;Hepatocyte Transplantation: Quo Vadis? Int J Radiat Oncol Biol Phys. 2018 Nov 29.&nbsp;&nbsp;PMID: 30503786</p>
<p>10.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Lundgren G, Ohri N, Tom&eacute;, WA, Kalnicki S, Garg MK. Early Response Assessment on Mid-Treatment CT Predicts Loco-Regional Recurrence in Oropharyngeal Cancer Patients Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1036-1045; PMID: 29779936</p>
<p>11.&nbsp;<strong>Kabarriti R</strong>, Baliga S, Ohri N, Guha C, Kalnicki S, Garg, MK. Radiotherapy for Patients With Newly Diagnosed Metastatic Head and Neck Squamous Cell Carcinoma.&nbsp;&nbsp;Head and Neck, 2018 Dec 16.&nbsp;&nbsp;PMID: 30556318</p>
<p>12. &nbsp;Barahman M, Zhang W, Yaffe Harris H, Aiyer A,&nbsp;<strong>Kabarriti R</strong>, Kinkhabwala M, Roy-Chowdhury N, Beck AP, Scanlan TS, Roy-Chowdhury J, Asp P, Guha C. Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.&nbsp;&nbsp;J Hepatol. 2019 Jan 14.&nbsp;&nbsp;PMID: 30654068</p>
<p>13.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Ahmed S, Vogelius I, Guha C, Kalnicki S, Tom&eacute; WA, Garg MK.&nbsp;&nbsp;Origin of Locoregional Recurrences After Definitive Intensity-modulated Radiation Therapy (IMRT) for Laryngeal Cancer Determined Based on Follow-up PET/CT Imaging.&nbsp;&nbsp;Cureus. 2019 Jan 8;11(1):e3856; PMID: 30899607</p>
<p>14. &nbsp;Jiang JM, Ohri N, Tang J, Moadel R, Cynamon J, Kaubisch A, Kinkhabwala M, Garg MK, Guha C,&nbsp;<strong>Kabarriti R</strong>.&nbsp;&nbsp;Centers with More Therapeutic Modalities are Associated with Improved Outcomes for Patients with Hepatocellular Carcinoma.&nbsp;&nbsp;Journal of Gastrointestinal Oncology, 2019 Jun;10(3):546-553. PMID: 31183206</p>
<p>15.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Ohri N, Narang R, Huang R, Chuy JW, Rajdev LN, Kalnicki S, Guha C, Garg MK.&nbsp;&nbsp;Human Papillomavirus, Radiation Dose and Survival of Patients with Anal Cancer. Acta Oncolgica, 2019 Jul 8:1-7, PMID: 31282249</p>
<p>16. &nbsp;Zhu S, Brodin NP, English K, Ohri N, Chuy JW, Rajdev LN, Narang R, Kalnicki S, Guha C, Garg MK,&nbsp;<strong>Kabarriti R. &nbsp;</strong>Comparing Outcomes Following Total Neoadjuvant Therapy and Following Neoadjuvant Chemoradiation Therapy in Patients with Locally Advanced Rectal Cancer.&nbsp;EClinicalMedicine, in Press</p>

EMR ID

54490

Biography

<p class="MsoNormal">Rafi Kabarriti, MD, is a cum laude graduate of Columbia University with a bachelor&rsquo;s degree in biochemistry and economics.</p><p class="MsoNormal">Dr. Kabarriti earned his medical degree at Albert Einstein College of Medicine and completed a residency in internal medicine at St. Luke&rsquo;s-Roosevelt Hospital Center and a residency in radiation oncology at Montefiore Medical Center, where he was chief resident in the Department of Radiation Oncology.</p><p class="MsoNormal">Dr.Kabarriti is the recipient of the 2014 Young Investigator Award given by the Conquer Cancer Foundation and the American Society of Clinical Oncology. In addition, his abstracts have been selected for oral presentations at national and international meetings including the annual meetings of the American Society for Radiation Oncology. Dr. Kabarriti is author and co-author of articles published in peer-reviewed journals including <i>the International Journal of Radiation Oncology</i><i>&bull;Biology</i><i>&bull;Physics</i>, <i>Hepatology International</i>, and <i>PLoS One</i>.</p>

Is Open Scheduling

Off

Chandan Guha

https://assets.montefioreeinstein.org/profiles/images/physphoto/Guha_Chandan_MD_420x504.jpg

First Name

Chandan

Last Name

Guha

NPI

1093917924

Faculty ID

7020

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Exploring therapeutic potential of stem cell regeneration in the event of radiation insult </strong><br />Exposure to high doses of ionizing radiation in the event of therapeutic, accidental or intentional incident such as nuclear/radiological warfare can lead to debilitating injuries to multiple organs resulting in death within days depending on the amount of radiation dose and the quality of radiation. Unfortunately, there is not a single FDA-licensed drug approved against acute radiation injury.</p>
<p>Radiation damage to multiple organs often described as multiple organ dysfunction syndrome (MODS) or acute radiation syndrome (ARS) results from rapid depletion of radiosensitive cells, these cells are usually the stem or progenitor cells with high proliferative capacity; naturally, bone marrow stem cells (BMSC), and intestinal stem cells (ISC), which are extremely critical in maintaining a pool of peripheral blood cells and in maintaining villi for the absorption of nutrients are highly sensitive to radiation. One of the most efficient ways of rescuing MODS is to administer fresh cells that can repair, support and/or replace the damaged cells and repopulate the damaged tissue with healthy cells. The Rad-Stem Center for Medical Countermeasures against Radiation (RadStem CMCR) program at Einstein is developing stem cell-based therapies to treat acute radiation syndrome (ARS) that results from radiation injury.</p>
<p>Radiation-induced gastrointestinal syndrome (RIGS) results from a combination of direct damage to intestinal crypt and endothelial cells, and subsequent loss of the mucosal barrier leading to microbial infection, septic shock and systemic inflammatory response syndrome (SIRS). Currently, there is no treatment for RIGS in clinic. Irradiation induces apoptosis of crypt ISC, endothelial cells and enterocytes within hours. Acute loss of cells in situ requires rapid compensation of their functions and this is best achieved using cell replacement therapies. We are interested in exploring intestinal regenerative therapy with a combination of systemic administration of growth factors and cell replacement therapy to salvage Gl function post-radiation exposure. We are testing combinations of: a) intestinal stem cell growth factor, R-spondinl (R-spol), b) TLR ligands, and c) transplantation of bone marrow-derived endothelial progenitor cells (EPC) and mesenchymal stem cells (MSC) to restore IR-damaged ISC niche, protect against IR-induced cell death and provide growth signals for host ISC regeneration, thus providing protection and mitigation from RIGS.</p>
<p><strong>Preparative live irradiation for hepatocyte transplant in acute liver injury and cirrhosis </strong><br />Hepatocyte transplantation (HT) is a very attractive alternative to liver transplant in the treatment of both inherited and acquired liver diseases. However, benefits of this procedure are currently limited by the inability of the transplanted hepatocytes to proliferate in the host liver, and lack of a noninvasive method to evaluate the repopulation of transplanted hepatocytes in the liver. In order to develop a clinically feasible protocol for HT, we are exploring preparative hepatic irradiation (HIR) for liver repopulation (in place of liver transplant) to deplete host hepatocytes and permit preferential proliferation of the engrafted donor cells in response to hepatic mitotic stimuli.<strong> &nbsp;</strong>Our lab was the first one to demonstrate that preparative HIR and partial hepatectomy (PH), followed by HT results in the replacement of virtually all host hepatocytes by the transplanted non-irradiated hepatocytes in 12 weeks. We are interested in using inducible pluripotent stem cells (iPSC)- derived hepatocytes following highly focused irradiation of the damaged liver in place of a liver transplant. We are also interested in exploring non-invasive biomarkers to validate that the transplanted hepatocytes can efficiently replace host hepatocytes upon liver irradiation.</p>
<p><strong>Cancer Immunotherapy </strong><br />Radiation therapy (RT) has been used as a standard treatment modality for many solid tumors. While tumoricidal properties of RT are instrumental for standard clinical application, irradiated tumors can potentially serve as a source of tumor antigens <em>in vivo</em>, where dying tumor cells would release various tumor antigens slowly over time. Using different<em> in vitro</em> and <em>in vivo</em> tumor models we, and others, demonstrated that RT enhances oxidative stress, and augments the release of necessary activating signals for DC such as endogenous danger associated molecular pattern (DAMP) molecules from irradiated cells. These RT-mediated processes lead to an increase antigenecity of irradiated cells which augments antigen presentation leading to an effective anti-tumoral immune responses. However the underlying mechanism of this processes has still to be determined.</p>
<p>Over the last years we have been interested in designing novel tumor vaccines that amplify the tumor immune response using conventional and exploratory cancer therapies. In particular we are focusing on evaluating the immunogenic properties of radiation therapies and determine how immunotherapeutic molecules can synergize with RT in boosting immune cells cell function. We are also interested in exploring therapeutic effect of ultrasound therapy in the treatment of solid tumor. Our recent work on use of Listeria-based vaccine therapy in combination of RT shows that this strategy is more effective than RT alone.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Guha is a radiation oncologist who specializes in prostate, genitourinary, liver and GI malignancies, and radio surgery. His research interests include development of stem-cell based therapies to treat radiation-induced toxicity and prevent death in patients.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Immunomodulation of radiation therapy: Radiation-enhanced tumor vaccines</strong></p>
<ol>
<li>Ahmed MM, Guha C, Hodge JW, Jaffee E. Immunobiology of Radiotherapy: New Paradigms. Radiat Res. 2014, Aug;182(2):123-5</li>
<li>Almo SC, Guha C. Considerations for Combined Immune Checkpoint Modulation and Radiation Treatment. Radiat Res. 2014, Aug;182(2):230-8</li>
<li>Kawashita Y, Deb NJ, Garg M, Kabarriti R, Alfieri A, Takahashi M, Roy-Chowdhury J, Guha C. An Autologous In Situ Tumor Vaccination Approach for Hepatocellular Carcinoma. Flt3 Ligand Gene Transfer Increases Antitumor Effects of a Radio-Inducible Suicide Gene Therapy in an Ectopic Tumor Model. Radiat Res. 2014 Aug;182(2):201-10</li>
<li>Bernstein, Michael B; Garnett, Charlie T; Zhang, Huogang; Velcich, Anna; Wattenberg, Max M; Gameiro, Sofia R; Kalnicki, Shalom; Hodge, James W; Guha, Chandan. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer biotherapy &amp; radiopharmaceuticals, 2014 May; 29 (4):153-61</li>
<li>Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res. 2013 Nov;1(5):280-4</li>
<li>Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One. 2013 Jul 24;8(7)</li>
<li>Zhang, Huagang; Liu, Laibin; Yu, Dong; Kandimalla, Ekambar R; Sun, Hui Bin; Agrawal, Sudhir; Guha, Chandan. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PloS one, 2012; 7 (5)</li>
<li>Hannan, Raquibul; Zhang, Huagang; Wallecha, Anu; Singh, Reshma; Liu, Laibin; Cohen, Patrice; Alfieri, Alan; Rothman, John; Guha, Chandan. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer immunology, immunotherapy: CII, 2012 Dec; 61 (12):2227-38</li>
</ol>
<p><strong>Stem cell based therapy for radiation injury</strong></p>
<ol>
<li>Benderitter, Marc; Caviggioli, Fabio; Chapel, Alain; Coppes, Robert P; Guha, Chandan; Klinger, Marco; Malard, Olivier; Stewart, Fiona; Tamarat, Radia; Luijk, Peter Van; Limoli, Charles L. Stem Cell Therapies for the Treatment of Radiation-Induced Normal Tissue Side Effects. Antioxidants &amp; redox signaling, 2014, Jul 10;21(2):338-55</li>
<li>Zachman, Derek K; Leon, Ronald P; Das, Prerna; Goldman, Devorah C; Hamlin, Kimberly L; Guha, Chandan; Fleming, William H. Endothelial cells mitigate DNA damage and promote the regeneration of hematopoietic stem cells after radiation injury. Stem cell research, 2013 Nov; 11 (3):1013-21</li>
<li>Saha, Subhrajit; Bhanja, Payel; Liu, Laibin; Alfieri, Alan A; Yu, Dong; Kandimalla, Ekambar R; Agrawal, Sudhir; Guha, Chandan, &lsquo;TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome&rsquo;; PloS one, 2012; 7 (1)</li>
<li>Saha, Subhrajit; Bhanja, Payel; Kabarriti, Rafi; Liu, Laibin; Alfieri, Alan A; Guha, Chandan,. Bone marrow stromal cell transplantation mitigates radiation-induced gastrointestinal syndrome in mice. PloS one, 2011; 6 (9)</li>
<li>Bhanja P, Saha S, Kabarriti R, Liu L, Roy-Chowdhury N, Roy-Chowdhury J, Sellers RS, Alfieri AA, Guha C. Protective role of R-spondin1, an intestinal stem cell growth factor, against radiation-induced gastrointestinal syndrome in mice. PLoS One. 2009 Nov 24;4(11)</li>
</ol>
<p><strong>Preparative irradiation to facilitate liver cell repopulation and stem cell engraftment <em>in vivo</em></strong></p>
<ol>
<li>Vainshtein, Jeffrey M; Kabarriti, Rafi; Mehta, Keyur J; Roy-Chowdhury, Jayanta; Guha, Chandan. Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. International journal of radiation oncology, biology, physics, 2014 Jul 15; 89 (4):786-803</li>
<li>Vainshtein, Jeffrey M; Kabarriti, Rafi; Mehta, Keyur J; Roy-Chowdhury, Jayanta; Guha, Chandan. Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. International journal of radiation oncology, biology, physics. 2014 Jul 15; 89 (4):786-803</li>
<li>Yannam, Govardhana Rao; Han, Bing; Setoyama, Kentaro; Yamamoto, Toshiyuki; Ito, Ryotaro; Brooks, Jenna M; Guzman-Lepe, Jorge; Galambos, Csaba; Fong, Jason V; Deutsch, Melvin; Quader, Mubina A; Yamanouchi, Kosho; Kabarriti, Rafi; Mehta, Keyur; Soto-Gutierrez, Alejandro; Roy-Chowdhury, Jayanta; Locker, Joseph; Abe, Michio; Enke, Charles A; Baranowska-Kortylewicz, Janina; Solberg, Timothy D; Guha, Chandan; Fox, Ira J. A nonhuman primate model of human radiation-induced venocclusive liver disease and hepatocyte injury. International journal of radiation oncology, biology, physics, 2014 Feb 1; 88 (2):404-11</li>
<li>Miyazaki, Kensuke; Yamanouchi, Kosho; Sakai, Yusuke; Yamaguchi, Izumi; Takatsuki, Mitsuhisa; Kuroki, Tamotsu; Guha, Chandan; Eguchi, Susumu, &lsquo;Construction of liver tissue in&yacute;&yacute;vivo with preparative partial hepatic irradiation and growth stimulus: investigations of less invasive techniques and progenitor cells&rsquo;; The Journal of surgical research. 2013 Dec; 185 (2):889-95</li>
<li>Puppi, Juliana; Strom, Stephen C; Hughes, Robin D; Bansal, Sanjay; Castell, Jose V; Dagher, Ibrahim; Ellis, Ewa C S; Nowak, Greg; Ericzon, Bo-Goran; Fox, Ira J; Gomez-Lechon, M Jose; Guha, Chandan; Gupta, Sanjeev; Mitry, Ragai R; Ohashi, Kazuo; Ott, Michael; Reid, Lola M; Roy-Chowdhury, Jayanta; Sokal, Etienne; Weber, Anne; Dhawan, Anil, &lsquo;Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London&rsquo;; Cell transplantation. 2012; 21 (1):1-10</li>
<li>Zhou, Hongchao; Dong, Xinyuan; Kabarriti, Rafi; Chen, Yong; Avsar, Yesim; Wang, Xia; Ding, Jianqiang; Liu, Laibin; Fox, Ira J; Roy-Chowdhury, Jayanta; Roy-Chowdhury, Namita; Guha, Chandan. Single liver lobe repopulation with wildtype hepatocytes using regional hepatic irradiation cures jaundice in Gunn rats. PloS one. 2012; 7 (10)</li>
<li>Ding, Jianqiang; Yannam, Govardhana R; Roy-Chowdhury, Namita; Hidvegi, Tunda; Basma, Hesham; Rennard, Stephen I; Wong, Ronald J; Avsar, Yesim; Guha, Chandan; Perlmutter, David H; Fox, Ira J; Roy-Chowdhury, Jayanta. Spontaneous hepatic repopulation in transgenic mice expressing mutant human &yacute;&yacute;1-antitrypsin by wild-type donor hepatocytes. The Journal of clinical investigation, 2011 May; 121 (5):1930-4</li>
<li>Soltys, Kyle A; Soto-Gutierrez, Alejandro; Nagaya, Masaki; Baskin, Kevin M; Deutsch, Melvin; Ito, Ryotaro; Shneider, Benjamin L; Squires, Robert; Vockley, Jerry; Guha, Chandan; Roy-Chowdhury, Jayanta; Strom, Stephen C; Platt, Jeffrey L; Fox, Ira J. Barriers to the successful treatment of liver disease by hepatocyte transplantation. Journal of hepatology, 2010 Oct; 53 (4):769-74</li>
<li>Dawson, Laura A; Guha, Chandan. Hepatocellular carcinoma: radiation therapy. Cancer journal (Sudbury, Mass.), 2008 Mar-Apr; 14 (2):111-6</li>
<li>Agoni, Lorenzo; Basu, Indranil; Gupta, Seema; Alfieri, Alan; Gambino, Angela; Goldberg, Gary L; Reddy, E Premkumar; Guha, Chandan. Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. International journal of radiation oncology, biology, physics, 2014 Apr 1; 88 (5):1180-7</li>
</ol>

EMR ID

4049

Is Open Scheduling

Off

Rasim A. Gucalp

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e88015b0-09f1-11ed-be8f-e58d49e7c7df.jpg

First Name

Rasim

Last Name

Gucalp

NPI

1295815785

Faculty ID

4777

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Rasim Gucalp&rsquo;s research interests include novel therapies in lung cancer as well as supportive care in cancer patients. He is actively involved in the multidisciplinary care of patients with lung cancer and central nervous system tumors. He is a member of several Montefiore Medical Center/Albert Einstein College of Medicine committees including the institutional tumor board, faculty senate, Pharmacy and Therapeutic Committee, and COGME.</p>
<p>A native of Turkey, Dr. Gucalp received his medical degree at Hacettepe University School of Medicine in Ankara, Turkey. After completing his medical residency at Downstate Medical Center in Brooklyn, he came to Montefiore Medical Center to complete his oncology fellowship. He is the director of the Hematology/Oncology Fellowship Program at Montefiore, and serves as a professor of Clinical Medicine at Albert Einstein College of Medicine.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3765

Is Open Scheduling

Off

Kira Gritsman

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6b993220-5d55-11ef-92db-0be6da54f487.jpg

First Name

Kira

Last Name

Gritsman

NPI

1174598148

Faculty ID

14128

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>The Roles of Signaling Pathways in Adult Blood Development and Leukemia</strong></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">The Gritsman lab studies the signal transduction pathways that affect the early fate decisions of adult hematopoietic stem cells (HSCs) as they progress from an undifferentiated multipotent state to the generation of differentiated blood cells.&nbsp; When these early fate decisions go awry, this can lead to the formation of leukemia-initiating cells. We are interested in</span><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;how signaling pathways affect the self-renewal and differentiation of HSCs and malignant or pre-malignant stem cells in myeloid malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).</span></p>
<p><strong>Roles of the PI3 kinase isoforms in adult blood development</strong></p>
<p>PI3 kinase (PI3K) is a lipid kinase that is important for the regulation of metabolism, the cell cycle, apoptosis, and protein synthesis. &nbsp;In hematopoietic cells, there are four isoforms of the catalytic subunit of PI3K, each encoded by a separate gene. &nbsp;Emerging evidence suggests that these isoforms have unique functions in normal and cancer cells, but may substitute for each other in some contexts.&nbsp; We have generated a series of mouse knockout models that allow us to study the roles of each of these isoforms individually in adult hematopoiesis.&nbsp; For example, we have found that the p110alpha isoform is most important for red cell development, but is not required in normal blood stem cells. We have now also generated compound knockout mice to determine the redundant roles of the PI3K isoforms in blood development. &nbsp;We recently reported that PI3K isoforms play important redundant roles during the hematopoietic stress response, such as after chemotherapy. However, deletion of all 3 Class IA PI3K isoforms leads to a phenotype with impaired HSC differentiation, resembling myelodysplastic syndrome (MDS). We are studying how deletion of PI3K will impact normal HSC function, including self-renewal, proliferation, and differentiation along different blood lineages by affecting processes such as autophagy and epigenetic regulation in HSCs.</p>
<p><strong>Roles of the PI3 kinase isoforms in leukemia</strong></p>
<p>Acute myeloid leukemia (AML) is a genetically diverse disease, but activation of the PI3K pathway has been reported in up to 80% of cases.&nbsp; A subset of AML cell lines and AML patient samples respond to PI3K pathway inhibitors, but it is unclear how patients should be selected for potential response to these inhibitors. &nbsp;We found that RAS-mutated myeloid leukemias are particularly dependent on the p110alpha isoform of PI3K, and that pharmacologic inhibition of p110alpha can be used to treat both RAS-mutated cell lines and RAS-mutated leukemia in mice. Furthermore, we use cell lines, patient samples, and mouse models of leukemia to investigate the mechanisms of resistance to PI3K inhibition, with the goal of identifying new drug targets and designing new combination treatments for leukemia that incorporate PI3K inhibitors.</p>
<p><strong>RON Kinase in Myeloproliferative Neoplasms</strong></p>
<p>The myeloproliferative neoplasms (MPNs) are a group of diseases that are caused by kinase mutations in HSCs, which lead to uncontrolled proliferation of myeloid cells. The Philadelphia chromosome-negative MPNs are characterized by mutations in the JAK/STAT signaling pathway, and respond to JAK inhibitors, but resistance often develops. We recently discovered that the receptor Tyrosine kinase RON can physically interact with JAK2 in MPN cells, leading to potentiation of JAK/STAT signaling in resistant cells. Furthermore, we found that pharmacologic or genetic inactivation of RON can inhibit proliferation of MPN cells and re-sensitize resistant cells to JAK inhibitors.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;"><strong><span style="font-size: 10.5pt; font-family: Verdana, sans-serif; color: #201f1e;">Member of the Cancer Dormancy and Tumor Microenvironment Institute&nbsp;</span></strong></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">The Gritsman lab&rsquo;s research interests include the contributions of signaling pathways to leukemic and pre-leukemic stem cell dormancy in minimal residual disease, which includes mechanisms of immune evasion. Furthermore, the Gritsman lab is interested in the roles of inflammatory signaling pathways and of the local microenvironment in bone marrow fibrosis, and in the evolution of myeloid neoplasms from the pre-malignant to malignant state. Our major goals are to identify opportunities for therapeutic targeting to prevent the transition from the pre-leukemic state to leukemia, or to eliminate minimal residual disease to prevent relapse.</span></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><a name="_GoBack"></a><span style="font-size: 11pt; font-family: Arial, sans-serif;">Ames, K.,&nbsp;^&nbsp;Kaur,^&nbsp;I., Shi, Y., Tong, M., Sinclair, T., Hemmati, S., Glushakow-Smith, S.G., Tein,&nbsp;&nbsp;E., Gurska, L., Steidl, U., Dubin, R., Shan, J., Montagna, C., Pradhan, K., Verma, A., and&nbsp;<strong><u>Gritsman, K.</u></strong>, Deletion of PI3-Kinase Promotes Myelodysplasia Through Dysregulation of Autophagy in Hematopoietic Stem Cells,&nbsp;<strong><em>Science Advances</em></strong><em>&nbsp;2023.&nbsp;</em>doi:&nbsp;<a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.o…; target="_blank" rel="noopener"><span style="color: black; text-decoration: none;">10.1126/sciadv.ade8222</span></a><u>,&nbsp;</u>PMID:&nbsp;36812307</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><em><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></em></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Folgado Marco, V., Ames, K., Chuen, J.,&nbsp;<strong><u>Gritsman, K.</u></strong>&nbsp;&amp; Baker, N.,&nbsp;Haploinsufficiency of the essential gene&nbsp;<em>RpS12</em>&nbsp;causes defects in erythropoiesis and hematopoietic stem cell maintenance,&nbsp;<em>&nbsp;<strong>eLife</strong>&nbsp;</em>2023&nbsp;Jun 5;12:e69322. doi: 10.7554/eLife.69322.&nbsp;PMID:&nbsp;37272618</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gurska, L.M., Okabe, R., Schurer, A., Tong, M.M., Soto, M., Choi, D., Ames, K., Glushakow-Smith, S., Montoya, A., Tein, E., Miles, L.A., Cheng, H., Hankey-Giblin, P., Levine, R.L., Goel, S., Halmos, B., and&nbsp;<strong><u>Gritsman, K.</u></strong>&nbsp;Crizotinib has Preclinical Efficacy in Philadelphia-negative Myeloproliferative Neoplasms,&nbsp;<strong><em>Clinical Cancer Research</em></strong>&nbsp;2022&nbsp;Dec 20:CCR-22-1763. doi: 10.1158/1078-0432.CCR-22-1763. PMID:&nbsp;36537918</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gurska, L., Ames, K., and&nbsp;<strong><u>Gritsman, K</u></strong>, Signaling Pathways in Leukemic Stem Cells,&nbsp;</span><span style="font-size: 11pt; font-family: Arial, sans-serif; color: #333333; letter-spacing: 0.2pt; background-color: #fcfcfc;">In: Zhang H., Li S. (eds) Leukemia Stem Cells in Hematologic Malignancies.&nbsp;<strong>Advances in Experimental Medicine and Biology</strong>, vol 1143. Springer, Singapore</span><span style="font-size: 11pt; font-family: Arial, sans-serif;">, July 24, 2019, doi:&nbsp;<a href="https://doi.org/10.1007/978-981-13-7342-8_1"><span style="color: black; letter-spacing: 0.2pt; background-color: #fcfcfc; text-decoration: none;">https://doi.org/10.1007/978-981-13-7342-8_1</span></a><span style="letter-spacing: 0.2pt; background-color: #fcfcfc;">;&nbsp;</span>PMID:&nbsp;31338813, PMCID:&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7249489/&quot; target="_blank" rel="noopener"><span style="color: black; text-decoration: none;">PMC7249489</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Hemmati, S., Sinclair, T., Tong, M., Bartholdy, B., Okabe, R.O., Ames, K., Ostrodka, L., Haque, T., Kaur, I., Mills, T. S., Agarwal, A., Pietras, E.M., Zhao, J.J., Roberts, T.M., and&nbsp;<strong><u>Gritsman, K.</u></strong>, PI3 kinase alpha and delta promote hematopoietic stem cell activation,&nbsp;<strong><em>JCI Insight&nbsp;</em></strong>2019&nbsp;doi.org/10.1172/jci.insight.125832</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Mitchell, K., Barreyro, L., Todorova, T., Taylor, S., Antony-Debre, I., Narayanagari, S., Carvajal, L., Leite, J., Piperdi, Z., Pendurti, G., Mantzaris, I., Paietta, E., Verma, A.,&nbsp;<strong><u>Gritsman, K.,&nbsp;</u></strong>and Steidl, U. IL1RAP potentiates multiple oncogenic signaling pathways in AML,&nbsp;<strong><em>Journal of&nbsp;Experimental Medicine</em></strong><em>.&nbsp;</em>2018 May 17. doi: 10.1084/jem.20180147,&nbsp;PMID: 29773641</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Hemmati, S., Haque, T., and&nbsp;<strong><u>Gritsman, K</u>,&nbsp;</strong>Inflammatory Signaling Pathways in Pre-leukemic and Leukemic Stem Cells,&nbsp;<strong><em>Frontiers in Oncology</em></strong><em>&nbsp;</em>2017 Nov 13;7:265. doi: 10.3389/fonc.2017.00265</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Bhagat, T.D., Chen, S., Bartenstein, M., Barlowe, A.T., Von Ahrens, D., Choudhary, G.S., Tivnan, P., Amin, E., Marcondes, M., Sanders, M.A., Hoogenboezem, R.M., Kambhampati, S., Ramanchandra, N., Mantzaris, I., Sukrithan, V., Laurence, R., Lopez, R. Bhagat, P., Giricz, O., Sohal, D., Wickrema, A., Yeung, C.,&nbsp;<strong><u>Gritsman, K.,</u></strong>&nbsp;Aplan, P., Hochedlinger, K., Yu, Y., Pradhan, K., Zhang, J., Greally, J.M., Mukherjee, S., Pellagatti, A., Boultwood, J., Will, B., Steidl, U., Raaijmakers, M.H.G.P., Deeg, H.J., Kharas, M.G. and Verma, A. Epigenetically Aberrant Stroma in MDS Propagates Disease Via Wnt/b-Catenin Activation, 2017&nbsp;<strong><em>Cancer Research</em></strong>&nbsp;2017 Jul 6. pii: canres.0282.2017. doi: 10.1158/0008-5472</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Yuzugullu, H., Baitsch, L., Von, T., Steiner, A., Tong, H., Ni, J., Clayton, L., Bronson, R., Roberts, T.,&nbsp;<strong><u>Gritsman, K</u></strong><u>.</u>, and Zhao, J.J. A p110b-Rac signaling loop mediates Pten-loss-induced perturbation of hematopoiesis and leukemogenesis.&nbsp;<strong><em>Nature Communication</em></strong><em>s&nbsp;</em>October 7,2015, doi:10.1038/NCOMMS9501</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., Weigert, O., Kopp, N., Wu, S-C., Kim, S., Liu, H., Tivey, T., Christie, A.L.,&nbsp;<strong><u>Gritsman, K.</u></strong>,&nbsp; Gotlib, J., Deininger, M., Turley, S., Tyner, J., Marto, J., Weinstock, D.M., and Lane, A.A. Mutations in G-protein beta subunits promote transformation and kinase inhibitor resistance&nbsp;<strong><em>Nature Medicine</em></strong><em>&nbsp;</em>2015 (1):71-5.</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><strong><u><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gritsman, K</span></u></strong><strong><span style="font-size: 11pt; font-family: Arial, sans-serif;">.</span></strong><span style="font-size: 11pt; font-family: Arial, sans-serif;">, Yuzugullu, H., Von, T., Yan, H., Clayton, L., Fritsch, C., Maira, S.-M., Hollingworth, G., Choi, C., Khandan, T., Paktinat, M., Okabe, R.O., Roberts, T.M., and Zhao, J.J. &nbsp;Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha<strong>.&nbsp;<em>Journal of Clinical Investigation&nbsp;</em></strong>2014;124(4):1794&ndash;1809.&nbsp;http://www.jci.org/articles/view/69927</span></p&gt;
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Kharas, M.G. and&nbsp;<strong><u>Gritsman, K</u></strong>. Akt: A Double-Edged Sword for Hematopoietic Stem Cells.&nbsp;<strong><em>Cell Cycle</em>&nbsp;</strong>2010; Vol 9; Issue 7</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Kharas, M.G., Okabe, R., Ganis, J.J., Gozo,M., Khandan,T., Paktinat, M., Gilliland, D.G., and&nbsp;<strong><u>Gritsman, K</u>.</strong>&nbsp;Constitutively Active AKT Depletes Hematopoietic Stem Cells and Induces Leukemia in Mice.&nbsp;<strong><em>Blood&nbsp;</em></strong>2010; 115(7): 140615&nbsp;http://www.bloodjournal.org/content/115/7/1406</span></p&gt;
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>

EMR ID

73180

Is Open Scheduling

Off

David S. Geller

https://assets.montefioreeinstein.org/profiles/images/Geller_David_S_MD_2x.jpg

First Name

David

Last Name

Geller

NPI

1467437764

Faculty ID

10675

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Geller is a full-time faculty member of the Orthopaedic Surgery Department at Montefiore Medical Center and serves as the director of the Orthopaedic Oncology Service, managing both pediatric and adult patients.&nbsp; He is the co-director of Orthopaedic Surgery at the Montefiore Medical Center Moses Campus and currently serves as the Quality Improvement Officer for the Montefiore Cancer Committee.&nbsp; His clinical focus involves primary and metastatic bone and soft tissue tumors, with a secondary interest in joint replacement in the setting of extensive bone loss.&nbsp; He has experience in navigation-guided surgery, allograft reconstruction, endoprosthetic reconstruction, and use of custom or patient-tailored reconstructive prostheses.&nbsp; His research interests include expression patterns in osteosarcoma, surgical margins in osteosarcoma, novel drug screening methods and targeted therapy for osteosarcoma using novel therapeutic modalities.&nbsp; He is extensively involved in resident and medical student education.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Geller is an orthopaedic surgeon specializing in musculoskeletal oncology and joint replacement, and his practice encompasses adult and pediatric patients. Dr. Geller’s research interests include surface receptor expression in osteosarcoma and potential targeted therapies for the treatment of osteosarcoma. He has developed a novel murine xenograft model for osteosarcoma for the evaluation of surgical margins in osseous tumor surgery. His research additionally includes allograft bone reconstruction techniques, resonance frequency changes during joint reconstruction and pain management in the elderly orthopaedic population.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Orthopedic oncology, orthopedic surgery, bone and soft tissue sarcomas, benign bone and soft-tissue tumors, metastatic carcinoma on the bone </p>

Research Focus

<p>Osteosarcoma, with an interest in innovative treatment strategies for both local disease control and metastatic disease; evaluation of expression patterns in osteosarcoma and surgical margins using a xenograft osteosarcoma murine model; the functional role of bone morphogenetic proteins in osteosarcoma surgery; use of intraoperative navigation techniques for tumor surgery; tumorigenesis of osteosarcoma </p>

Elsevier Profile

PubMed.gov URL

Selected Publications

<ul>
<li>Morris J, Dutcher J, <strong>Geller DS</strong>. Revisiting the Orhtopaedic Management of Metastatic Renal Cell Carcinoma: Rationale for a More Aggressive Approach. <em>Current Orthopaedic Practice. </em>2013 Sept/Oct; 24(5):547-551.</li>
<li>Bekarev M, Elsinger EC, Villanueva-Siles E, Borzykowski RM, <strong>Geller DS.</strong> Synovial Sarcoma of the Foot. <em>Journal of Foot and Ankle Surgery</em>. 2013 Jul-Aug; 52(4):513-7. doi: 10.1053</li>
<li>Capogna BM, Lovy A, Blum Y, Kim SJ, Flesen UR, <strong>Geller DS.</strong> Infection Rate Following Total Joint Arthroplasty in the HIV Population. <em>Journal of Arthroplasty</em>. 2013 Sep; 28(8):1254-8. doi: 10.1016</li>
<li>Lall A, Hohn E, Kim M, Gorlick R, Abraham J, <strong>Geller DS</strong>. Comparison of Surface Area Across the Allograft-Host Junction Site Using Conventional and Navigated Osteotomy Technique. <em>Sarcoma</em>. 2012; 2012:197540.&nbsp;</li>
<li>Piperdi S, Austin-Page L, <strong>Geller DS</strong>, Ahluwalia M, Gorlick S, Gill J, Sellers R, Zhang W, Li N, Ching Sohak, Gorlick R. Beta-Catenin Does Not Confer Tumorigenicity when Introduced into Partially Transformed Human Mesenchymal Stem Cells.<em> Sarcoma</em>. 2012. Epub 2012 Oct 18.</li>
<li>Crocco L, Gorlick R,<strong> Geller DS</strong>. Current Practice Management Regarding Thromboembolic Prophylaxis Within the Pediatric Sarcoma Patient Population, <em>Journal of Pediatric Hematology/Oncology</em>.2012 Sep 19. [Epub ahead of print]</li>
<li>&nbsp;Hall GL, Villanueva-Siles E, Borzykowski RM, Gruson KI, Dorfman HD, <strong>Geller</strong> <strong>DS</strong>. Aspergillus osteomyelitis of the proximal humerus: a case report. <em>Skeletal Radiology</em>. 2012 Aug; 41(8):1021-5. Epub 2012 Mar 31.</li>
<li>Sambaziotis C, Plymale M, Lovy A, O&rsquo;Halloran K, McCulloch K, <strong>Geller DS</strong>. Pseudoaneurysm of the Distal Thigh after Manipulation of a Total Knee Arthroplasty. <em>Journal of Arthroplasty</em>. 2012 Aug; 27(7); 1414.</li>
<li>Shakked RJ, <strong>Geller DS</strong>, Gorlick R, Dorfman HD. Mesenchymal chondrosarcoma: Clinicopathologic study of 20 cases. <em>The Archives of Pathology &amp; Laboratory Medicine</em>.&nbsp; 2012 Jan; 136(1):61-75.</li>
<li>Hohn E, Garfein ES, Mehta KJ, <strong>Geller DS. </strong>Quadriceps Tendon Allograft Augmentation after Wide Excision of a Soft Tissue Sarcoma. <em>Current Orthopaedic Practice</em>. 2012 Jan/Feb; 23(1):68-71.</li>
<li>Singh CK, <strong>Geller DS. </strong>The Telescopic Mating Technique for Bulk Allograft Reconstruction. <em>Orthopaedics</em>. 2012 Feb; 35(2):118-124.</li>
<li>Sambaziotis C, Lovy A, Moadel RM, Chamarthy M, Glaser J, Jaini S, Villanueva-Siles E, <strong>Geller DS</strong>. Florine-18 Fluorodeoxyglucose Positron Emission Tomography for Osteochondromas Utilizing a Triple-Time Point Protocol.&nbsp; <em>Open Journal of Medical Imaging</em>. 2011 Dec; 1(2):15-20.</li>
<li>Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, <strong>Geller DS. </strong>Cell Surface Receptor Expression Patterns in Osteosarcoma. <em>Cancer.</em> 2011 Feb 1; 118(3):740-9.</li>
<li>Plymale M, Lovy A, Villanueva-Siles E, <strong>Geller DS.</strong> Isolated intra-articular pseudorheumatoid nodule of the knee.<em> Skeletal Radiology</em>. 2011 Apr; 40(4):463-6.</li>
<li>Green MC, Dorfman HD, Villanueva-Siles E, Gorlick RG, Thornhill BA, Weber RV, <strong>Geller DS. </strong>Aggressively Recurrent Infantile Myofibroma of the Axilla and Shoulder Girdle. A Case Report. <em>Skeletal Radiology</em>.2010 Mar; 40(3):357-61.</li>
<li><strong>Geller DS</strong>, Pope JB, Thornhill BA, Dorfman, HD. Cryptococcal pyarthrosis and sarcoidosis. <em>Skeletal Radiol</em>. 2009 Jul; 38(7):721-7.</li>
<li>Sah A, <strong>Geller DS</strong>, Mankin HJ, Delaney T, Rosenberg A, Wright C, Hornicek FJ. Malignant Transformation of Synovial Chondromatosis of the Shoulder to Chondrosarcoma - A Case Report," <em>Journal of Bone and Joint Surgery. </em>2007 Jun; 89(6):1321-8.</li>
<li><strong>Geller DS</strong>, Hornicek FJ, Mankin HJ, Raskin KA. &ldquo;Soft Tissue Sarcoma Resection Volume Associated with Wound-Healing Complications,&rdquo; <em>Clinical Orthopaedics and Related Research.</em> 2007; 457:182-5.</li>
<li>Ames JA, Abraham JA, <strong>Geller DS</strong>, Goldsmith J, Gebhardt MC.&nbsp; Proximal Tibial Lesion in a Young Adult: Early Diagnosis Allowing Unique Reconstruction.&nbsp; <em>The Orthopaedic Journal at Harvard Medical School.</em> 2006 Aug: 143-7.</li>
<li>Gardner MJ, Yacoubian S, <strong>Geller DS</strong>, Pode M, Mintz D, Helfet&nbsp; DL,&nbsp; Lorich DG. &ldquo;Prediction of Soft-Tissue Injuries in Schatzker II Tibial Plateau Fractures based on Measurements of Plain Radiographs,&rdquo; <em>Journal of Trauma-Injury Infection &amp; Critical Care</em>. 2006; 60(2):319-324.</li>
<li>Steinberg EL, <strong>Geller DS</strong>, Yacoubian SV, Shasha N, Dekel S, Lorich DG. &ldquo;Intramedullary Fixation of Tibial Shaft Fractures Using an Expandable Nail,&rdquo; <em>Journal of Orthopaedic Trauma.&nbsp; </em>2006 May; 20(5):303-9.</li>
<li>Gardner, MJ, Yacoubian S, <strong>Geller DS</strong>, Suk M, Mintz D, Potter H, Helfet DL, Lorich DG. &ldquo; The Incidence of Soft Tissue Injury in Operative Tibial Plateau Fractures,&rdquo; <em>Journal of Orthopaedic Trauma</em>.&nbsp; 2005; 19:79-84.</li>
<li>Lorich DG, Yacoubian SV, <strong>Geller DS</strong>. &ldquo;Intramedullary Fixation of Humeral Shaft Fractures Using an Inflatable Nail,&rdquo; <em>Orthopaedics</em>. 2003 Oct; 26(10):1011-4.</li>
<li>Lorich DG, <strong>Geller DS</strong>, Yacoubian SV, Leo AJ, Helfet DL. &ldquo;An Innovative Mode of Intramedullary Fixation,&rdquo; <em>International Review of Modern Surgery</em>, March 2002.</li>
<li>Westrich GH, <strong>Geller DS</strong>, O&rsquo;Malley MJ, Deland JT, Helfet DL. &ldquo;Anterior Iliac Crest Bone Graft Harvesting Using the Cortico-Cancellous Reamer System,&rdquo; <em>Journal of Orthopaedic Trauma</em>. 2001 Sep-Oct; 15(7):500-6.</li>
</ul>

EMR ID

4324

Biography

<p>David S. Geller is a board-certified orthopedic oncologist who specializes in the treatment of both pediatric and adult patients with bone and soft-tissue tumors. He has been a full-time faculty member at Montefiore since 2006. He is an Associate Professor of Orthopedic Surgery and Pediatrics at our Albert Einstein College of Medicine.</p><p>Dr. Geller is known for his expertise in musculoskeletal tumor surgery, with specific experience in bone and soft-tissue sarcomas, such as osteosarcoma, Ewing's sarcoma, liposarcoma and synovial sarcoma. He has extensive experience in managing patients with metastatic carcinoma of the bone as well. He routinely offers limb-salvage surgery using a wide array of reconstructive tools.</p><p>Dr. Geller earned his medical degree from Tel Aviv University's Sackler School of Medicine and completed an orthopedic surgery residency at Montefiore. He received his fellowship training from the Harvard Combined Orthopedic Oncology Program, which included Massachusetts General Hospital, Boston Children's Hospital, and Beth Israel Deaconess Medical Center.</p><p>Dr. Geller serves as the Associate Director of the Musculoskeletal Oncology Research Laboratory at Montefiore. He leads numerous translational research efforts designed to investigate the pathophysiology and molecular mechanisms of bone and soft tissue cancers. He is interested in improved surgical techniques and novel therapeutic approaches for primary malignant bone tumors. He is actively involved in collaborative clinical trials both nationally and internationally.</p><p>Dr. Geller is an active member of the American Academy of Orthopedic Surgeons, Muskuloskeletal Tumor Society, Connective Tissue Oncology Society, Children's Oncology Group, American Orthopedic Association, and the American Association for Cancer Research.</p>

Is Open Scheduling

Off